Back to top

Analyst Blog

Biogen Idec and partner, Swedish Orphan Biovitrum recently presented encouraging data on their hemophilia candidates, rFVIIIFc and rFIXFc. Results, which were presented at the annual meeting of the European Association for Haemophilia and Allied Disorders (EAHAD), showed that the candidates provided long-lasting protection from bleeding with fewer injections compared to the current standard of care for hemophilia patients.

The pharmacokinetic activity of rFVIIIFc (hemophilia A) and rFIXFc (hemophilia B) was compared to that of currently available treatments. Results showed that rFVIIIFc and rFIXFc stayed active in the body for a longer period of time thereby allowing the prevention of bleeding with fewer injections than currently required.

Biogen recently submitted a Biologics License Application (BLA) seeking US Food and Drug Administration (FDA) approval for rFIXFc for hemophilia B. Currently available treatments for hemophilia B include Pfizer’s (PFE - Analyst Report) BeneFIX.

Meanwhile, the US regulatory filing for rFVIIIFc for hemophilia A should also take place in the first half of 2013. A convenient dosing schedule (supported by a longer duration of action and a suitable safety profile) could help rFIXFc and rFVIIIFc capture share from existing products in the hemophilia market.

Upcoming Catalysts

Meanwhile, Biogen has some other significant pipeline catalysts coming up, the most important being an update on the regulatory status of Tecfidera (BG-12). Tecfidera , Biogen’s oral multiple sclerosis candidate, is currently under review in both the US and the EU. A response in the US should be out by March. We believe Tecfidera could become a leader in the oral multiple sclerosis market once launched.

Biogen currently carries a Zacks Rank #3 (Hold). Biotech companies that currently look interesting include Alkermes (ALKS - Analyst Report), which carries a Zacks #1 Rank (Strong Buy), and Elan , which carries a Zacks Rank #2 (Buy).

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
RPC INC RES 24.91 +8.35%
LITHIA MOTO… LAD 94.59 +4.60%
DELTA AIR L… DAL 39.15 +3.90%
FLAMEL TECH… FLML 14.51 +3.50%
SOUTHWEST A… LUV 28.87 +2.92%